CERo Therapeutics Holdings, Inc. Common Stock (NASDAQ:CERO) — Market Cap & Net Worth
Market Cap & Net Worth: CERo Therapeutics Holdings, Inc. Common Stock (CERO)
CERo Therapeutics Holdings, Inc. Common Stock (NASDAQ:CERO) has a market capitalization of $717.49K ($717.49K) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30398 globally and #5906 in its home market, demonstrating a -2.86% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CERo Therapeutics Holdings, Inc. Common Stock's stock price $0.03 by its total outstanding shares 21102671 (21.10 Million). Analyse CERo Therapeutics Holdings, Inc. Common cash conversion from operations to see how efficiently the company converts income to cash.
CERo Therapeutics Holdings, Inc. Common Stock Market Cap History: 2021 to 2026
CERo Therapeutics Holdings, Inc. Common Stock's market capitalization history from 2021 to 2026. Data shows change from $209.13 Million to $717.49K (-72.32% CAGR).
Index Memberships
CERo Therapeutics Holdings, Inc. Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #914 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2890 of 3165 |
Weight: CERo Therapeutics Holdings, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
CERo Therapeutics Holdings, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CERo Therapeutics Holdings, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CERO by Market Capitalization
Companies near CERo Therapeutics Holdings, Inc. Common Stock in the global market cap rankings as of May 4, 2026.
Key companies related to CERo Therapeutics Holdings, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
CERo Therapeutics Holdings, Inc. Common Stock Historical Marketcap From 2021 to 2026
Between 2021 and today, CERo Therapeutics Holdings, Inc. Common Stock's market cap moved from $209.13 Million to $ 717.49K, with a yearly change of -72.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $717.49K | -46.03% |
| 2025 | $1.33 Million | +5.00% |
| 2024 | $1.27 Million | -99.45% |
| 2023 | $232.13 Million | +7.11% |
| 2022 | $216.72 Million | +3.63% |
| 2021 | $209.13 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of CERo Therapeutics Holdings, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $717.49K USD |
| MoneyControl | $717.49K USD |
| MarketWatch | $717.49K USD |
| marketcap.company | $717.49K USD |
| Reuters | $717.49K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CERo Therapeutics Holdings, Inc. Common Stock
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.